Assessment of hepatic function employing hepatocyte specific contrast agent concentrations to multifactorially evaluate fibrotic remodeling.
Hepatic cirrhosis
contrast agent
magnetic resonance images
Journal
Quantitative imaging in medicine and surgery
ISSN: 2223-4292
Titre abrégé: Quant Imaging Med Surg
Pays: China
ID NLM: 101577942
Informations de publication
Date de publication:
01 Jul 2023
01 Jul 2023
Historique:
received:
23
08
2022
accepted:
04
04
2023
medline:
17
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
Diffuse parenchymal liver diseases are contributing substantially to global morbidity and represent major causes of deaths worldwide. The aim of our study is to assess whether established hepatic fat and iron quantitation and relaxometry-based quantification of hepatocyte-specific contrast material as surrogate for liver function estimation allows to evaluate liver fibrosis. Retrospective consecutive study. Seventy-two healthy patients (mean age: 53 years) without known liver disease, 21 patients with temporary elevated liver enzymes (mean: 65 years) and 109 patients with biopsy proven liver fibrosis or cirrhosis (mean: 61 years), who underwent liver magnetic resonance imaging (MRI) with a hepatocyte-specific contrast agent [gadoxetate disodium, gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA), 0.25 mmol/mL Primovist, Bayer AG, Leverkusen, Germany] at 1.5 T (n=133) and at 3 T (n=69), were included. Fibrosis was classified using the histopathological meta-analysis of histological data in viral hepatitis (METAVIR) and the clinical Child-Pugh scores. Gd-concentration were quantified using T1 map-based calculations. Gd-concentration mapping was performed by using a Look-Locker approach prior to and 912±159 s after intravenous administration of hepatocyte specific contrast agent. Additionally, parenchymal fat fraction, R2*, bilirubin, gender and age were defined as predicting factors. Diagnostic accuracy was calculated in a monoparametric (linear regression, predictor: Gd-concentration) and multiparametric model (predictors: age, bilirubin level, iron overload, liver fat fraction, Gd concentration in the left and right liver lobe). Mean Gd-concentration in the liver parenchyma was significantly higher for healthy patients ([Gd] =0.51 µmol/L) than for those with liver fibrosis or cirrhosis ([Gd] =0.31 µmol/L; P<0.0001) and with acute liver disease ([Gd] =0.28 µmol/L), though there were no significant differences for the latter two groups. There was a significant moderate negative correlation for the mean Gd-concentration and the METAVIR score (ρ=-0.44, P<0.0001) as well as for the Child-Pugh stage (ρ=-0.35, P<0.0001). There was a significant strong correlation between the bilirubin concentration and the Gd-concentration (ρ=-0.61, P<0.0001). The diagnostic accuracy for the discrimination of healthy patients and patients with known fibrosis or cirrhosis was 0.74 (0.71/0.60 sensitivity/specificity) in a monoparametric and 0.76 (0.85/0.61 sensitivity/specificity) in a machine learning based multiparametric model. T1 mapping-based quantification of hepatic Gd-EOB-DTPA concentrations performed in a multiparametric model shows promising diagnostic accuracy for the detection of fibrotic changes. Liver biopsy might be replaced by imaging examinations.
Sections du résumé
Background
UNASSIGNED
Diffuse parenchymal liver diseases are contributing substantially to global morbidity and represent major causes of deaths worldwide. The aim of our study is to assess whether established hepatic fat and iron quantitation and relaxometry-based quantification of hepatocyte-specific contrast material as surrogate for liver function estimation allows to evaluate liver fibrosis.
Methods
UNASSIGNED
Retrospective consecutive study. Seventy-two healthy patients (mean age: 53 years) without known liver disease, 21 patients with temporary elevated liver enzymes (mean: 65 years) and 109 patients with biopsy proven liver fibrosis or cirrhosis (mean: 61 years), who underwent liver magnetic resonance imaging (MRI) with a hepatocyte-specific contrast agent [gadoxetate disodium, gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA), 0.25 mmol/mL Primovist, Bayer AG, Leverkusen, Germany] at 1.5 T (n=133) and at 3 T (n=69), were included. Fibrosis was classified using the histopathological meta-analysis of histological data in viral hepatitis (METAVIR) and the clinical Child-Pugh scores. Gd-concentration were quantified using T1 map-based calculations. Gd-concentration mapping was performed by using a Look-Locker approach prior to and 912±159 s after intravenous administration of hepatocyte specific contrast agent. Additionally, parenchymal fat fraction, R2*, bilirubin, gender and age were defined as predicting factors. Diagnostic accuracy was calculated in a monoparametric (linear regression, predictor: Gd-concentration) and multiparametric model (predictors: age, bilirubin level, iron overload, liver fat fraction, Gd concentration in the left and right liver lobe).
Results
UNASSIGNED
Mean Gd-concentration in the liver parenchyma was significantly higher for healthy patients ([Gd] =0.51 µmol/L) than for those with liver fibrosis or cirrhosis ([Gd] =0.31 µmol/L; P<0.0001) and with acute liver disease ([Gd] =0.28 µmol/L), though there were no significant differences for the latter two groups. There was a significant moderate negative correlation for the mean Gd-concentration and the METAVIR score (ρ=-0.44, P<0.0001) as well as for the Child-Pugh stage (ρ=-0.35, P<0.0001). There was a significant strong correlation between the bilirubin concentration and the Gd-concentration (ρ=-0.61, P<0.0001). The diagnostic accuracy for the discrimination of healthy patients and patients with known fibrosis or cirrhosis was 0.74 (0.71/0.60 sensitivity/specificity) in a monoparametric and 0.76 (0.85/0.61 sensitivity/specificity) in a machine learning based multiparametric model.
Conclusions
UNASSIGNED
T1 mapping-based quantification of hepatic Gd-EOB-DTPA concentrations performed in a multiparametric model shows promising diagnostic accuracy for the detection of fibrotic changes. Liver biopsy might be replaced by imaging examinations.
Identifiants
pubmed: 37456296
doi: 10.21037/qims-22-884
pii: qims-13-07-4284
pmc: PMC10347321
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4284-4294Informations de copyright
2023 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-22-884/coif). The authors have no conflicts of interest to declare.
Références
Indian J Pediatr. 2007 Apr;74(4):393-9
pubmed: 17476087
Magn Reson Imaging. 1996;14(3):243-53
pubmed: 8725190
Invest Radiol. 2005 Nov;40(11):715-24
pubmed: 16230904
Eur J Radiol. 2021 Aug;141:109789
pubmed: 34051684
Dig Dis. 2010;28(1):155-61
pubmed: 20460905
J Clin Invest. 2005 Feb;115(2):209-18
pubmed: 15690074
J Hepatol. 2013 Jul;59(1):160-8
pubmed: 23511777
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Gut. 1979 Feb;20(2):137-40
pubmed: 428825
Liver Transpl. 2004 Aug;10(8):995-1000
pubmed: 15390325
J Magn Reson Imaging. 2013 Feb;37(2):398-406
pubmed: 23011874
Invest Radiol. 2011 Apr;46(4):277-83
pubmed: 21343827
Am J Gastroenterol. 1991 Oct;86(10):1508-13
pubmed: 1928047
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Clin Gastroenterol Hepatol. 2015 Mar;13(3):440-451.e6
pubmed: 25305349
Hepatology. 1996 Aug;24(2):289-93
pubmed: 8690394
Clin Radiol. 2015 Oct;70(10):1096-103
pubmed: 26164421
Radiol Med. 2021 Sep;126(9):1149-1158
pubmed: 34105102
Dig Liver Dis. 2017 Jul;49(7):789-795
pubmed: 28237298
Eur Radiol. 2012 Jun;22(6):1224-32
pubmed: 22302503
Eur J Radiol. 2021 Nov;144:109993
pubmed: 34656047
J Magn Reson Imaging. 2009 Nov;30(5):1042-6
pubmed: 19856436
Radiographics. 2009 Oct;29(6):1591-614
pubmed: 19959510
Eur J Radiol. 2014 Jun;83(6):900-904
pubmed: 24661616
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Ultrasound Med Biol. 2003 Dec;29(12):1705-13
pubmed: 14698338
Hepatology. 2012 Jun;55(6):2005-23
pubmed: 22488764
Radiology. 2011 Sep;260(3):727-33
pubmed: 21712472
Sci Rep. 2022 Mar 18;12(1):4716
pubmed: 35304554
Hepatology. 2005 Jun;41(6):1282-9
pubmed: 15834937
Eur Radiol. 2015 Oct;25(10):2869-79
pubmed: 25903702
Gastroenterology. 2008 Jul;135(1):32-40
pubmed: 18471441
AJR Am J Roentgenol. 2015 Jul;205(1):22-32
pubmed: 25905647